ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Cycloastragenol reduces inflammation and apoptosis in acute lung injury by inhibiting the NF-κB p65 and Akt pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cycloastragenol, a triterpenoid saponin extracted from Astragalus membranaceus, exerts several pharmacological effects. However, its mechanism of action in acute lung injury treatment remains unclear. This study was conducted to test the hypothesis that cycloastragenol can inhibit lipopolysaccharide (LPS)-induced acute lung injury and investigate the underlying molecular mechanisms. This study systematically explored the effects and mechanism of action of cycloastragenol in LPS-induced acute lung injury treatment using network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation. Gene Ontology and Kyoto Encyclopedia of Gene and Genomes enrichment analyses indicated that the effects of cycloastragenol are mediated by inflammation- and apoptosis-related genes. Both in vitro and in vivo experiments were conducted to assess the effectiveness of cycloastragenol in acute lung injury treatment. Lung function was evaluated using a pulmonary function test system with indicators, such as peak expiratory flow, minute ventilation, and lung resistance. The expression of inflammatory factors and apoptosis-related proteins was evaluated using Western blot analysis, quantitative real-time polymerase chain reaction, and immunofluorescence. Apoptosis in lung tissue and mouse primary peritoneal macrophages was assessed using terminal deoxynucleotidyl transferase dUTP nick-end labelling staining and flow cytometry, respectively. Cycloastragenol effectively alleviated pulmonary dysfunction and edema, mitigated histopathological damage, and suppressed the activation of both the NF-κB p65 and Akt signaling pathways induced by LPS, ultimately leading to reduced inflammation and apoptosis. The results suggest that cycloastragenol alleviates acute lung injury by exerting anti-inflammatory and anti-apoptotic effects. These findings suggest that cycloastragenol could be a potential therapeutic candidate for preventing and treating ALI.
Indexed as
Identifiers
41263996What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.